The European Partnership for Personalized Medicine (EP PerMed) is a platform for the coordination of national and European activities in the field of personalized medicine. EP PerMed unites earlier European initiatives under one roof and is a continuation of the ERA PerMed program. The second call, “Pharmacogenomic strategies for personalized medicine approaches (PGxPM2025),” will be open until February 18, 2025 for pre-proposals and June 17, 2025, for full proposals.

Target group

The funding program is aimed at researchers working in the field of personalized medicine at universities, non-academic research institutions, and research departments in related sectors. 

Funding goals

EP PerMed aims to improve health outcomes within sustainable healthcare systems through research and the development, innovation, and implementation of personalized medicine approaches for the benefit of patients, citizens, and society.

Funding period and funding amount

Up to 36 months

Requirements

The requirements and specifications for the FWF programs Principal Investigator Projects or Clinical Research apply.

Information on the current call “Pharmacogenomic strategies for personalized medicine approaches (PGxPM2025)”

This call is intended to fund research projects in all disease areas. Consortia must be transnational, interdisciplinary, and cross-sectorial; the application must clearly describe the personalized medicine perspective of the proposed research.

The overall objectives of the JTC2025 will be to

  • Support research projects in human health on pharmacogenomic strategies for personalized medicine approaches that address one or more of the following aspects:
    • Identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination
    • Validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes
    • Applying pharmaco-omics strategies to determine the right dosage, the efficacy of treatments, and/or the risk of adverse drug response and non-response to treatment to tailor personalized treatment pathways, including combined treatments (multi-medication)
  • Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, engaging a range of other relevant disciplines
  • Encourage cross-sectorial collaborations by including the private sector, industry, as well as regulatory/HTA agencies, and patient organizations

Each application must be supported by a minimum of three and a maximum of six partners from at least three participating partner countries, whereby a joint document must be submitted to the central Call Secretariat by the coordinator.

The researchers are funded by their respective national/regional funding organization.

Funding organizations from 23 countries are planning to join this call. Please see the PGxPM2025 website for the current list of participating countries.

Approval

Decided by the Scientific Board based on a recommendation of the Call Secretariat

Application information

Applications are submitted online using the Call Secretariat’s system. Please see the PGxPM2025 website for a link to the application submission system.

There will be a two-step submission and review procedure.

  • Deadline for pre-proposal submission: February 18, 2025 (2:00 pm CET)
  • Deadline for full proposal submission: June 17, 2025 (2:00 pm CET) 
  • Funding decision: expected in October 2025

In addition to the application submitted to the Call Secretariat, administrative and financial data as well as academic abstracts (in accordance with the FWF guidelines for Principal Investigator Projects) must also be submitted to the FWF using the online portal elane. In the pre-proposal stage, proposals are submitted under the program category “PIK – International Projects – pre-proposal” (deadline February 19, 2025, 2:00 pm Vienna local time). For the full proposal stage, applicants must choose the program category “PIN – International Projects” (deadline June 18, 2025, 2:00 pm Vienna local time).

Please note that the research institution must approve the proposal for submission by the deadlines indicated above. To do so, research institutions must be registered on the FWF research institution portal.

Both steps are mandatory.

Funding institution 

Austrian Science Fund (FWF)

Further information

  • Please see the PGxPM2025 website for further details.
  • For general questions about the call, please contact the Joint Call Secretariat (JCS) at permed(at)dlr.de. For specific questions related to the budget, criteria, and rules of your funding organization, please consult your funding organization directly. Contacts and details of the national and regional regulations of the individual funding organizations can be found in the call text on the PGxPM2025 website.

Please note:

Pre-proposals: December 16, 2024 to February 18, 2025 (2:00 pm CET)

Full proposals: approximately May 16 to June 17, 2025 (2:00 pm CET)

Submissions

Dec. 16, 2024 to Feb. 18, 2025 (02:00 pm Vienna local time)

Inquiries and contact

Dr. Hannes Zwickl
hannes.zwickl(at)fwf.ac.at
+43 676 83487 8219

Scroll to the top